Compare Natera Inc. Common Stock (NTRA) vs Ovintiv Inc. (DE) (OVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Ovintiv Inc. (DE) — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Ovintiv Inc. (DE) trades at $66.75 (market cap $18.44B). The key difference: Natera Inc. Common Stock is far larger — about 3.1× Ovintiv Inc. (DE)'s market cap, and Ovintiv Inc. (DE) pays a 1.8% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Ovintiv Inc. (DE) for 6 Days on average.
| NTRA | OVV | |
|---|---|---|
Market Cap | $57.03B | $18.44B |
Volume | 1,131,157 | 3,495,725 |
Sector | Health | Energy |
52-Week High | $425.64 | $66.97 |
52-Week Low | $179.42 | $35.97 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $22.77B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
OVV trades at $66.66, up 2.36% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing robust revenue growth. Recent news highlights expansion in Permian and Montney assets, share buybacks, and strong free cash flow generation, positioning the stock for potential upside.
The outlook for OVV is positive, driven by operational strength and strategic acquisitions, though risks include commodity price volatility and natural gas headwinds. With a consensus price target of $76.00 and no sell ratings, Wall Street sentiment remains bullish, offering a favorable risk-reward profile for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Ovintiv Inc. (DE)
Ovintiv explores for and produces oil and natural gas in North America. Its operations are concentrated in major U.S. and Canadian resource basins.
Read more on OVV →
